At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 122 enrolled
Drug / intervention
Brolucizumabdrug
Likely dose
Brolucizumab 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
One Year, Single Arm, Open Label, Multicenter, Phase IV Study Using Multimodal Imaging to Guide Disease Activity Assessment Through Innovative Early Predictive Anatomical Biomarkers of Fluid Resolution in wAMD Patients Treated With Brolucizumab- IMAGINE Study
In Brief
A Phase 4 clinical trial evaluating Brolucizumab for Neovascular Age-related Macular Degeneration. Completed, enrolled 122 participants across 20 sites.
Detailed Summary
The purpose of this study was to identify innovative early imaging parameters as predictors of the long-term clinical response to brolucizumab in terms of fluid resolution in patients with wet Age-related Macular Degeneration (wAMD) to evaluate their potential in supporting the choice of treatment regimen (q12w or q8w).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesItaly
Collaborators--
Timeline
Phase 4CompletedFinished
20222023202420252026
First PostedMar 2021
Enrollment StartOct 2021
Primary CompletionOct 2023
TodayJul 2026
First PostedMar 1, 2021
Enrollment StartOct 15, 2021
Primary CompletionOct 4, 2023
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 5.3 years ago
Interventions
Brolucizumabdrug
120 mg/ml solution for intravitreal injection